Search

everythinglearnresearchcommunity

for

Search:↓

A 30-year-old male has been on finasteride/dutasteride for 3 years, with stable but still receding hairline, and blood tests showing high total testosterone but normal DHT and free testosterone levels. Despite challenges in gaining muscle, he maintains a good physique with a consistent lifting routine and recently improved results with creatine.

A hair transplant experience after 6 months, with 4100 grafts, which took 3 months to stop looking obvious and included finasteride treatment. It also discusses the differences between DHI and FUE methods.

The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

The conversation provides a detailed list of blood tests recommended before starting finasteride to establish a baseline for monitoring potential side effects. A shorter list is also provided for those with limited funds, and the user shares personal experience of using finasteride without issues for about nine years.

The conversation discusses using finasteride for 2 years and dutasteride for 6 months to treat hair loss, resulting in significant improvement. The user did not experience side effects and did not use other treatments like minoxidil, supplements, or micro-needling.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

The conversation is about updates on hair loss treatments Breezula or PTD-DBM. No new information was provided.

The user switched from finasteride to dutasteride due to side effects and is experiencing fewer side effects with dutasteride, though some scalp itching has occurred. Blood tests show elevated testosterone and estrogen, low DHT, and normal liver and cholesterol levels, leading the user to feel confident in the long-term benefits of dutasteride for hair regrowth.

The conversation is about a user planning a blood test to monitor health while on hair loss treatments: Finasteride, Minoxidil, and Dutasteride. Recommendations include testing for androgens, thyroid function, micronutrients, and basic health markers, with additional suggestions for PSA, prolactin, and estradiol.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The user shared their experience with hair loss treatments, including oral and topical Finasteride and Minoxidil, and detailed various blood test results to track hormonal changes. They noted that while DHT levels initially decreased with topical Finasteride, they later increased, but they observed positive results in hair growth.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

The user shared their experience with dutasteride for hair loss prevention, noting side effects like muscle weakness and brain fog, and observed increased testosterone levels. They recommend starting with a low dose and adjusting based on individual needs and blood work results.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The user has been using finasteride for hair loss since January 2023, initially seeing improvement but now experiencing increased thinning. They are considering other factors like thyroid and insulin resistance and are seeking advice from long-term finasteride users, while some suggest trying dutasteride, minoxidil, or consulting a dermatologist for further evaluation.

The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.

A user is exploring Kadeso, a product with Capilia Longa™ for hair regrowth, and seeks real-world experiences, comparing it to Minoxidil and Finasteride. They are interested in results, timeframe, side effects, and the credibility of the product's founder.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

A user experienced hair regrowth after 6 months on finasteride, which is earlier than the usual 12-18 months observed by their dermatologist. The dermatologist noted this as an exceptionally good response.

The conversation discusses the potential long-term effects of stopping finasteride after extended use, with differing opinions on the existence and prevalence of post-finasteride syndrome (PFS). Some users report persistent side effects, while others argue that such effects are rare or unrelated to the medication.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.

Treatments for hair loss, specifically the use of minoxidil, finasteride and RU58841. Replies to this post suggest that users should share relevant information publicly rather than through direct messages.